NexgenRx Inc.
NXG.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.78% | 12.37% | 8.40% | 1.87% | -1.78% |
| Total Other Revenue | 23.27% | 47.08% | 87.96% | 163.99% | 255.63% |
| Total Revenue | 17.01% | 13.43% | 10.27% | 4.46% | 0.84% |
| Cost of Revenue | 23.47% | 18.09% | 14.14% | 12.36% | 14.64% |
| Gross Profit | 15.27% | 12.20% | 9.24% | 2.44% | -2.34% |
| SG&A Expenses | 12.80% | 13.25% | 11.68% | 9.90% | 17.17% |
| Depreciation & Amortization | -5.10% | -4.68% | -7.05% | -10.44% | -9.17% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.32% | 12.48% | 10.22% | 8.12% | 13.45% |
| Operating Income | 2,362.42% | 213.56% | 16.21% | -145.18% | -101.42% |
| Income Before Tax | 284.42% | 103.45% | 26.33% | -294.98% | -111.99% |
| Income Tax Expenses | -84.01% | -83.00% | -83.13% | -82.87% | 107.32% |
| Earnings from Continuing Operations | 182.73% | 90.51% | 69.00% | -8,256.67% | -109.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 182.73% | 90.51% | 69.00% | -8,256.67% | -109.06% |
| EBIT | 2,362.42% | 213.56% | 16.21% | -145.18% | -101.42% |
| EBITDA | 48.93% | 16.17% | 3.48% | -28.88% | -57.78% |
| EPS Basic | 178.79% | 88.46% | 68.18% | -1,066.67% | -109.27% |
| Normalized Basic EPS | 258.33% | 116.67% | 33.33% | -281.82% | -113.95% |
| EPS Diluted | 155.26% | 70.97% | 51.85% | -375.00% | -111.41% |
| Normalized Diluted EPS | 263.64% | 116.67% | 50.00% | -337.50% | -113.92% |
| Average Basic Shares Outstanding | 0.68% | 0.56% | 0.35% | 0.14% | 0.07% |
| Average Diluted Shares Outstanding | -0.31% | -0.38% | -0.54% | 0.55% | -1.25% |
| Dividend Per Share | 100.00% | -1.33% | 94.74% | -3.90% | -51.95% |
| Payout Ratio | 3.01% | -8.93% | -4.12% | -1.01% | -7.04% |
